Jung et al. found that celecoxib might have a CD133 modulation effect, so they synthesized a PET probe 89Zr-DFO-AC133.1, which targeted the glycosylated epitope of CD133, validated its CD133 targeted imaging specificity in human colon adenocarcinoma HT29 xenografts and tested six-day short-term CD133 level monitoring post-celecoxib-treatment [57]. Here, PROM1 is linked to colon adenocarcinoma.